Novo Nordisk vows to bring innovation in BD market

Novo Nordisk, one of the global leading companies in diabetic care, has expressed its strong commitment to continue bringing its latest innovative insulin products in Bangladesh to serve the diabetic patients with different ranges of healthcare demand.
"Our commitment is to bring innovation in the Bangladesh market," Camilla Sylvest, vice president, Novo Nordisk, Business Area Oceania South East Asia, International Operations, told the FE in an interview recently.
Ms Sylvest was in Dhaka marking the launching of the company's new basal insulin product "Tresiba" in the local market.
As part of this commitment to the Bangladesh market, Novo Nordisk is expecting to launch another new innovative insulin product in the next year 2015, she said.
"We look forward to bringing another new innovation in Bangladesh in 2015," Ms Sylvest continued.
The 2015 product has already been developed but yet to be launched in any country, she said and shared different features of the insulin product, to be launched in Bangladesh next year.
Saying about recently launched "Tresiba", Ms Sylvest said that the product will be manufactured in Denmark, headquarter of Novo Nordisk, and later be imported to Bangladesh for the patients here. "It's very new product."
Structure and size of the product is like a white-board pen, as such the basal insulin is very easy to carry with the patients and to use even during the traveling period; the easy usage facility is one of the main features of the new insulin product.
With price of about Tk 2,400, each Tresiba contains 300 units of insulin. Having requirement of 10-unit insulin per day, the diabetic patient can use a Tresiba maximum 30 days.
Once-daily Tresiba provides an ultra-long duration of action beyond 42 hours, allowing flexibility in day-to-day dosing time, when needed with a minimum of eight hours between injections, without compromising efficacy or risk of hypoglycaemia.
Before the recent launching of the product in Bangladesh, Novo Nordisk covered eight more countries with this new product; Bangladesh is the ninth country, where Tresiba was launched, she said.
When asked about the next innovation of Novo Nordisk, Ms Sylvest said that we have wide ranges of innovation for bringing in the Bangladesh market; under its continuous research and development, the company plans to "bring another innovative insulin product in Bangladesh market in the next year."
"Our focus is to bring different ranges of products" to meet different kinds of demand of the different patients, the Novo Nordisk high official said.
In a query about the company's activities under the Corporate Social Responsibility (CSR), she said that they spent a lot of money, time and energy in this connection.
In collaboration with the Diabetic Association of Bangladesh (DAB), an official said, the Novo Nordisk is doing various activities including creation of awareness about diabetes and its free screening.
The company is providing both technical and financial assistance to the DAB to continue the activities under CSR. The Novo Nordisk official, however, refrained from saying details about it.
Headquartered in Denmark, the global healthcare company has 90 years of innovation and leadership in diabetes care.
Novo Nordisk has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy; it employs approximately 38,000 employees in 75 countries, and markets its products in more than 180 countries around the world.